-
Product Insights
Systolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Systolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Systolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Diastolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Diastolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Diastolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2023’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Myocardial Infarction – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Infarction - Drugs In Development, 2023’, provides an overview of the Myocardial Infarction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Huntington Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Huntington Disease - Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenzavirus A Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenzavirus A Infections - Drugs In Development, 2023’, provides an overview of the Influenzavirus A Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenzavirus A Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Neucardin in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Neucardin in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neucardin in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLY-2608 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLY-2608 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLY-2608 in Cervical Cancer Drug Details: RLY-2608 is under development for...